Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Kei Hara is active.

Publication


Featured researches published by Kei Hara.


FEBS Letters | 2004

Voltage-gated sodium channel expressed in cultured human smooth muscle cells: involvement of SCN9A

Taisuke Jo; Taiji Nagata; Haruko Iida; Hiroyuki Imuta; Kuniaki Iwasawa; Ji Ma; Kei Hara; Masao Omata; Ryozo Nagai; Hajime Takizawa; Takahide Nagase; Toshiaki Nakajima

Voltage‐gated Na+ channel (INa) is expressed under culture conditions in human smooth muscle cells (hSMCs) such as coronary myocytes. The aim of this study is to clarify the physiological, pharmacological and molecular characteristics of INa expressed in cultured hSMCs obtained from bronchus, main pulmonary and coronary artery. INa, was recorded in these hSMCs and inhibited by tetrodotoxin (TTX) with an IC50 value of approximately 10 nM. Reverse transcriptase/polymerase chain reaction (RT‐PCR) analysis of mRNA showed the prominent expression of transcripts for SCN9A, which was consistent with the results of real‐time quantitative RT‐PCR. These results provide novel evidence that TTX‐sensitive Na+ channel expressed in cultured hSMCs is mainly composed of Nav1.7.


Respirology | 1997

Thromboxane inhibition and monocrotaline-induced pulmonary hypertension in rats.

Taiji Nagata; Yoshio Uehara; Kei Hara; Kouichi Igarashi; Hisanori Hazama; Tetsuya Hisada; Kenjiro Kimura; Atsuo Goto; Masao Omata

Abstract Monocrotaline (MCT)‐induced pulmonary hypertension (PH) is a useful model for the investigation of this disorder in humans. The role of thrombocytes in the genesis of PH has already been addressed; however, the exact mechanism by which they induce PH remains to be elucidated. We investigated the effects of a thromboxane A2 (TXA2) synthase inhibitor (OKY‐046) and a TXA2/ prostaglandin H2 (PGH2) receptor antagonist (ONO‐8809) on the development of MCT‐induced PH. A single dose of MCT (60 mg/kg bodyweight; BW) was injected subcutaneously in Wistar rats 24 h after the administration of OKY‐046 or ONO‐8809. The TXA2 inhibitors were administered by gavage daily for 3 weeks. Urinary excretion of eicosanoids was determined by radioimmunoassay. At the end of the treatment period, the lungs, heart and kidneys were morphologically examined. The per cent medial thickness of the muscular pulmonary arteries (%MT) and the ratio of the right to the left ventricular mass including the septum (RV/LV+S) increased significantly in MCT‐treated rats compared with the control rats. The %MT was attenuated by the administration of ONO‐8809. Either OKY‐046 or ONO‐8809 attenuated the increase in RV/LV+S. In addition, both TXA2 inhibitors reduced urinary excretion of 11‐dehydro‐TXB2, particularly during the early phase of PH, suggesting that platelet aggregation was reduced. These findings suggest that the inhibition of TXA2 by synthase inhibition or receptor antagonism reduces or delays the development of MCT‐induced PH in rats, probably by inhibiting platelet aggregation.


British Journal of Cancer | 1999

Activation of cyclin D1-related kinase in human lung adenocarcinoma

Kouichi Igarashi; T Masaki; Yasushi Shiratori; W Rengifo; Taiji Nagata; Kei Hara; Teruaki Oka; J Nakajima; T Hisada; E Hata; Masao Omata

Cyclin D1 gene amplification is an important event in many cancers, but it is rarely found in non-small-cell lung cancer (NSCLC). This study was conducted in an attempt to clarify any other mechanisms related to cyclin D1 involvement in the malignant transformation of NSCLC, and we clearly showed for the first time that cyclin D1-related kinases are activated in NSCLC, especially in adenocarcinoma but not in squamous cell carcinoma. The results of this study strongly suggest that enhanced cyclin D1-related kinase activity could contribute to a progression of adenocarcinoma in NSCLC.


Internal Medicine | 2002

Oxygenation abnormalities in normoxemic patients with mild liver cirrhosis.

Taiji Nagata; Akihiro Matsumoto; Yoshio Uehara; Goh Tanaka; Hitoshi Oonuma; Kei Hara; Kouichi Igarashi; Hisanori Hazama; Yasunobu Hirata; Yasushi Shiratori; Masao Omata


Internal Medicine | 2012

Clinically Mild Encephalitis/Encephalopathy with a Reversible Splenial Lesion due to Mycoplasma pneumoniae Infection

Hideki Shibuya; Kou Osamura; Kei Hara; Tetsuya Hisada


Internal Medicine | 2009

Mucosa Associated Lymphoid Tissue (MALT) Lymphoma of the Thymus with Trisomy 18

Mitsuhiro Sunohara; Kei Hara; Kou Osamura; Naoki Tashiro; Hideki Shibuya; Kazuki Nakahara; Yukiko Kishida; Kouichi Tamura; Tetsuya Hisada


Internal Medicine | 2010

Microscopic polyangiitis accompanied by pleuritis as the only pulmonary manifestation of occupational silica exposure.

Hideki Shibuya; Hiroko Sano; Kou Osamura; Kosei Kujime; Kei Hara; Tetsuya Hisada


Internal Medicine | 2001

Microscopic polyangiitis associated with sinobronchial syndrome.

Taiji Nagata; Kei Hara; Teruaki Oka; Yasuhiro Yamauchi; Kouichi Igarashi; Hisanori Hazama; Masao Omata


Internal Medicine | 2008

An Adult Case of Multiple Squamous Papillomas of the Trachea Associated with Human Papilloma Virus Type 6

Hideki Shibuya; Tomoko Kutomi; Kosei Kujime; Kei Hara; Tetsuya Hisada


Haigan | 2006

A Case of Adenocarcinoma of the Lung with a Favorable Response to Retreatment with Gefitinib

Hideki Shibuya; Tomoko Kutomi; Yoko Sato; Naoki Tashiro; Kei Hara; Tetsuya Hisada

Collaboration


Dive into the Kei Hara's collaboration.

Top Co-Authors

Avatar

Tetsuya Hisada

National Defense Medical College

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Researchain Logo
Decentralizing Knowledge